Gonadotropin

Which Test is Best? OB-GYN Lauren Streicher, M.D. Offers Expert Advice on Selecting Pregnancy Tests

Retrieved on: 
Tuesday, February 13, 2024
Other Consumer, Women, Seniors, Retail, Teens, Parenting, Baby, Maternity, Convenience Store, Family, Online Retail, Consumer, General Health, Other Retail, Health, Other Education, Supermarket, Specialty, Education, Urination, Feinberg School of Medicine, Urine, Birth, HCG, Gonadotropin, Digital, Pregnancy, Placenta, Confusion, Pregnancy test, Patient, Birth control

Lauren Streicher , M.D., OB-GYN, clinical professor at Northwestern University Feinberg School of Medicine, addresses the most common questions about purchasing pregnancy tests, providing expert insight on which test to choose.

Key Points: 
  • Lauren Streicher , M.D., OB-GYN, clinical professor at Northwestern University Feinberg School of Medicine, addresses the most common questions about purchasing pregnancy tests, providing expert insight on which test to choose.
  • “When speaking to patients, I find there is still a lot of confusion as to which at-home pregnancy test is right for them.
  • Whether actively trying to conceive or not, having access to accurate and reliable pregnancy tests can alleviate any uncertainties.”
    Dr. Streicher sheds light on the following considerations regarding purchasing at-home pregnancy tests:
    How do at-home pregnancy tests work?
  • Pregnancy tests detect human chorionic gonadotropin (hCG), the hormone produced by the placenta during pregnancy that is found in urine.

Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment

Retrieved on: 
Monday, July 10, 2023
Health, Consumer, Women, Research, Science, Pharmaceutical, Biotechnology, Hypersensitivity, Vaginal bleeding, News, Gonadotropin, Ganirelix, Pregnancy, Anaphylaxis, Society, Ovarian hyperstimulation syndrome, Fresenius (company), American Society for Reproductive Medicine, Parent, Ovulation, LH, Woman, ART, Infertility, Multimedia, USP, Fertilisation, Luteinizing hormone, Abdominal pain, ML, Injection site reaction, Assisted reproductive technology, LaTeX, Patient, Physician, Risk, Injection, Fertility, HCG, SART, Nausea, Gonadotropin-releasing hormone, Reproductive medicine, FDA, Headache, Syringe, Pharmaceutical industry, Birth control, Organon

Fresenius Kabi announced today it has launched Ganirelix Acetate Injection, a generic fertility drug, as part of the company’s expansion in women’s health.

Key Points: 
  • Fresenius Kabi announced today it has launched Ganirelix Acetate Injection, a generic fertility drug, as part of the company’s expansion in women’s health.
  • Ganirelix Acetate Injection is available immediately from Fresenius Kabi in 250 mcg/0.5 mL prefilled syringes.
  • View the full release here: https://www.businesswire.com/news/home/20230710582430/en/
    Now available: Fresenius Kabi Ganirelix Acetate Injection.
  • Ganirelix Acetate Injection is the third product offering in Fresenius Kabi’s Women’s Health portfolio, which includes Chorionic Gonadotropin for Injection, USP (hCG) and Progesterone Injection, USP.

Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)

Retrieved on: 
Monday, June 12, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, ENDO, Endocrine Society, CAH, Gonadotropin, Poster, Adrenal insufficiency, Pharmaceutical industry

Spruce Biosciences, Inc .

Key Points: 
  • Spruce Biosciences, Inc .
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for the 105th Annual Meeting of the Endocrine Society (ENDO 2023) taking place June 15-18, 2023, in Chicago.
  • In a poster presentation, the company will highlight the effect of tildacerfont on gonadotropins and testicular steroidogenesis in men with classic congenital adrenal hyperplasia (CAH).
  • ENDO 2023 presentation details are as follows:
    Session Title: P72 – Clinical Adrenal and Pituitary: Adrenal Insufficiency
    The poster will be available on the company’s website beginning June 17, 2023, at 2:00 p.m. CT. Access more information about ENDO 2023 here .

Global Infertility Drugs Market Report 2022: Factors Increasing Infertility Cases in Men and Women Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023
Health, Pharmaceutical, Online, NICHD, Human services, Office of Inspector General, U.S. Department of Health and Human Services, Estrogen receptor, Online pharmacy, Hypogonadism, Cyst, Social stigma, Pharmacy, Cystic fibrosis, NIH, Bangladesh Technical Education Board, SERM, Obesity, Human development, Patient, Clomifene, Ovulation, PID, Diabetes, Smoking, Research, Bureau of Medical Services (U.S. Department of State), Infertility, Female, Dopamine, Menotropin, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Pelvic inflammatory disease, Letrozole, Prevalence, Hospital pharmacy, Endometriosis, Enzyme inhibitor, Men and Women, Urinary tract infection, Birth control, Woman, Gonadotropin

The Global Infertility Drugs Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 6.2 % CAGR during the forecast period.

Key Points: 
  • The Global Infertility Drugs Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 6.2 % CAGR during the forecast period.
  • The growing prevalence of infertility or the difficulty of bringing a baby to term throughout the world is what fuels the market for infertility medications.
  • Based on end-user, the infertility drugs Market is divided into Men and Women.
  • Based on distribution channel, the Infertility Drugs Market is divided into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy.

Global Infertility Drugs Market Report 2022: Sector to Reach $4.8 Billion by 2028 at a 6.2% CAGR

Retrieved on: 
Thursday, January 26, 2023
Online, Endometriosis, Hospital pharmacy, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Infertility, Female, Letrozole, Bangladesh Technical Education Board, Cyst, Ovulation, Office of Inspector General, U.S. Department of Health and Human Services, SERM, Pharmacy, Obesity, Pelvic inflammatory disease, Hypogonadism, Dopamine, Human services, PID, Urinary tract infection, Estrogen receptor, Smoking, Diabetes, Menotropin, Prevalence, NIH, Clomifene, Cystic fibrosis, Enzyme inhibitor, NICHD, Patient, Men and Women, Social stigma, Bureau of Medical Services (U.S. Department of State), Online pharmacy, Human development, Research, Birth control, Gonadotropin, Woman

The Global Infertility Drugs Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 6.2 % CAGR during the forecast period.

Key Points: 
  • The Global Infertility Drugs Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 6.2 % CAGR during the forecast period.
  • The growing prevalence of infertility or the difficulty of bringing a baby to term throughout the world is what fuels the market for infertility medications.
  • Based on distribution channel, the Infertility Drugs Market is divided into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy.
  • Based on drug class, the infertility drugs market is classified into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others.

Global Endocrine Testing Market Report 2022 to 2030: Players Include Agilent Technologies, Bio-Rad Laboratories, Biomerieux and Diasorin - ResearchAndMarkets.com

Retrieved on: 
Friday, December 30, 2022
Health, General Health, Government, Degenerative disease, LabCorp, National Institute of Diabetes and Digestive and Kidney Diseases, Kidney, Consciousness, Research, Digestive, Overweight, TSH, COVID-19, Laboratory, USD, Human body, Mass spectrometry, Pregnancy, Growth, Patient, Gonadotropin, Movement, Infection, American Diabetes Association, Physician, Endocrine system, FSH, Health, Maintenance, Hospital, HCG, Obesity, Thyroid, NIH, Diabetes, NIDDK, Prevalence, WHO, Endocrinology, Collaboration, Vaccine, Pharmaceutical industry, Immunoassay, Insulin

The global endocrine testing market is expected to reach USD 4.79 billion by 2030.

Key Points: 
  • The global endocrine testing market is expected to reach USD 4.79 billion by 2030.
  • The routine endocrine testing in individuals will help in overall maintenance of health and thus this awareness of better health is significantly contributing to the global endocrine testing market growth.
  • Such initiatives will drive the understanding of endocrine function in the human body and will further enable the endocrine testing market growth.
  • The market players are also expanding their regional presence due to various factors that are anticipated to grow the endocrine testing market.

Global Human Chorionic Gonadotropin Market Report 2022: Oligospermia Supports Demand for HCG Drugs and Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 29, 2022
Health, Other Health, Urine, Government, Ovulation, Egg, Oligospermia, Fertility, Infertility, Fertilisation, Female, DNA, Growth, Patient, Degenerative disease, Pregnancy, HCG, Gonadotropin, Safety, Cryptorchidism, Human chorionic gonadotropin, Hormone, Incidence, Woman, Renewable energy, Agriculture, Birth control

The "Global Human Chorionic Gonadotropin Market: Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Human Chorionic Gonadotropin Market: Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Global Human Chorionic Gonadotropin Market is having an exponential growth rate of 7.5% from 2022 to 2030.
  • For the purpose of this report, the technology segment of the global human chorionic gonadotropin market has been segmented into natural source extract and recombinant DNA technology.
  • Asia-Pacific is expected to be the most potential regional market for human chorionic gonadotropin market by 2030.

Pioneer in the Field of Reproductive Medicine Recognized for Lifetime Achievement

Retrieved on: 
Thursday, September 29, 2022
Olive, Health, BCAHRB Lifetime Achievement Award, Gynaecology, Woman, List of lifetime achievement awards, Elective surgery, Infertility, Gonadotropin, NIPT, Annual general meeting, Shoulder, Fertility, Growth, Nobel, University, TFP, IVF, Patient, Physician, Non-functional testing, General surgery, ART, Genetic testing, Family, Human, Reproductive medicine, Medicine, Laparoscopy, Obstetrics, Paganini Competition, Agriculture, Medical device, Birth control

VANCOUVER, Canada, Sep. 29, 2022 /PRNewswire-PRWeb/ -- Olive Fertility Centre is proud to announce that Dr. Al Yuzpe, co-director and co-founder of Olive Fertility Centre, Chief Medical Officer for The Fertility Partners, and a pioneer in reproductive medicine, received the 2022 Lifetime Achievement Award at the 68th Canadian Fertility and Andrology Society (CFAS) Annual Meeting.

Key Points: 
  • The Lifetime Achievement Award is a special recognition of an individual for extraordinary commitment and proven long-term contributions to the nonprofit CFAS and the field of reproductive science.
  • During his over 50-year career Dr Yuzpe has been internationally recognized for his pioneering work and has helped untold numbers of infertile couples realize their dream of having a family.
  • I am thrilled that he is receiving this prestigious award, as it demonstrates his dedication to the CFAS, as well as the greater field of assisted reproductive technology (ART)."
  • Not only has Dr Yuzpe been a visionary in the field of infertility, he has led the way in making family building accessible to all.

Pioneer in the Field of Reproductive Medicine Recognized

Retrieved on: 
Wednesday, September 28, 2022
Biotechnology, Alternative Medicine, Health, Family, Consumer, Pharmaceutical, Other Science, Research, Parenting, General Health, Other Consumer, Baby, Maternity, Science, Women, Olive, Gerald Loeb Lifetime Achievement Award winners, Gynaecology, List of lifetime achievement awards, Hormone, Gonadotropin, Infertility, Annual general meeting, Fertility, Growth, Learning, University, TFP, IVF, Patient, Physician, Technology, ART, Reproductive technology, Assisted reproductive technology, Human, Research, FSH, Reproductive medicine, Education, Obstetrics, Society, Birth control, Medical device, Public relations, Agriculture

Dr. Al Yuzpe, Chief Medical Officer for The Fertility Partners and a pioneer in reproductive medicine, was awarded The Lifetime Achievement Award at the 68th Canadian Fertility and Andrology Society (CFAS) Annual Meeting.

Key Points: 
  • Dr. Al Yuzpe, Chief Medical Officer for The Fertility Partners and a pioneer in reproductive medicine, was awarded The Lifetime Achievement Award at the 68th Canadian Fertility and Andrology Society (CFAS) Annual Meeting.
  • The Lifetime Achievement Award is a special recognition of an individual for extraordinary commitment and proven long-term contributions to the nonprofit CFAS and the field of reproductive science.
  • Referred to as the grandfather of in-vitro fertilization (IVF) in Canada, Dr. Yuzpe introduced new treatments, technologies, and procedures that revolutionized the field of fertility medicine in North America and worldwide.
  • I am thrilled that he is receiving this prestigious award, as it demonstrates his dedication to the CFAS, as well as the greater field of assisted reproductive technology (ART).

May Health Solidifies Veteran Executive Team with Appointment of Women’s Health Care Leader Anne Morrissey as CEO

Retrieved on: 
Friday, September 9, 2022
Medical Devices, Surgery, Women, Baby, Maternity, Clinical Trials, Other Health, Radiology, General Health, Consumer, Health, OBGYN, Patient, Degenerative disease, CEO, Technology, Acne, Female, Medtech, Sofinnova, Polycystic ovary syndrome, Gonadotropin, The Cooper Companies, Ovulation, PCOS, Chair, Menstruation, Health, Lead, Male, Hormone, IVF, Investment, Empathy, Type 2, Weight gain, Fertility, Leadership, Type 2 diabetes, Cooper, Yale University, Androgen, Risk, Institute of Health and Biomedical Innovation, Infertility, Face, Woman, Chief executive officer, Growth, Pregnancy, Management, Birth control, Astia

With Anne and Bob, May Health is guided by some of the most respected and accomplished leaders in the women's health care ecosystem, said Antoine Papiernik, chairman and managing partner at Sofinnova Partners, and the previous chairman of May Health.

Key Points: 
  • With Anne and Bob, May Health is guided by some of the most respected and accomplished leaders in the women's health care ecosystem, said Antoine Papiernik, chairman and managing partner at Sofinnova Partners, and the previous chairman of May Health.
  • Anne is an experienced executive and team builder who has devoted her career to making pregnancy and childbirth safer and more accessible.
  • I joined May Health to change the outlook for people living and struggling with the negative effects of PCOS, said Morrissey.
  • May Health is led by a team of serial medtech and womens health entrepreneurs and executives with extensive experience in product development, validation, and launch.